Genfit at the bottom of the SBF 120, down 7.5% over the week
The Lille-based biotech specializing in liver and metabolic diseases is losing ground in mid-morning trading, in a Paris market that is clearly trending downward. This decline follows a strong rebound begun at the end of October and a quarterly publication that had prompted reactions in both directions from the stock.
A decline that brings the share price back to its MM200
Genfit is down 3.22% at €10.22, while the stock remains among the largest decliners in the SBF 120, which is down 1.06%, as is the CAC 40.
The move brings the share price to €10.22, below the MM20 (€10.47, a gap of 2.39%) and close to the MM200 (€10.27). It nevertheless remains slightly above the MM50 (€10.15). This zone, where three moving averages converge, is the level the stock is testing this morning after a 21.67% gain over one month.
Over the week, the performance stands at -7.26%, and over three months at -21.51%. In a Paris market weighed down by tensions on French debt (10-year OAT at 4.93% as of November 16), the decline is therefore not sparing biotech stocks.
Iqirvo royalties, the foundation of the accounts published on November 5
The underlying picture can be read in the third-quarter financial information published on November 5: over nine months, royalties received on Iqirvo sales by Ipsen rose by 188% to €36.3 million, while total revenue declined to €36.4 million, compared with €39.2 million a year earlier.
The company indicates that these resources will fund its activities beyond the end of 2028. It also anticipates a possible new commercial milestone payment, and the peak sales forecast for Iqirvo has now been revised to €1 billion. Three phase 2 clinical trials (ACLF, CCA) have also been launched, with results expected in 2027.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.